Matinas BioPharma has appointed Jerome D. Jabbour, Co-founder and President of Matinas, as its Chief Executive Officer (“CEO”) and a member of its Board of Directors.
The clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, said that as part of a planned transition, Roelof Rongen has stepped down as CEO and a member of the Board. The Company also outlined its revised and streamlined clinical and regulatory strategy for lead antifungal program, MAT2203, following its recent successful meeting with the FDA and its plans for optimizing its proprietary cochleate nano-particle platform delivery technology to secure strategic collaborations in areas of innovative medicine.
Herb Conrad, Chairman of the Board of Matinas, said: “As we look to drive the Company forward into its next stage, it is evident that we need to embark on aggressive, yet focused strategies to fully realize the potential value associated with our technology platform. In preparing for this logical transition for some time, Jerry is intimately familiar with our delivery technology and product candidates and has developed valuable relationships and credibility with thought leaders and investors since joining the Company in 2013. The Board is confident that his vision and direction for the Company and demonstrated ability to execute are perfectly aligned with our strategic priorities moving forward. We are sincerely grateful to Roelof for his years of service to Matinas. He was integral in laying the foundation of the Company and positioning MAT2203 for a successful regulatory interaction with FDA in January 2018.”